Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

NCT02250326 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: nab-paclitaxel IV
DRUG: CC-486
DRUG: Duravalumab

Sponsor

Celgene